EGFR and prostate carcinoma: For example, nuclear translocation of epidermal growth factor receptor (EGFR) or androgen receptor (AR) associated with EVs released from prostate cancer cells and taken up by indolent receptor cells (i.e., cells without EGFR/AR) activated distinct signaling pathways in the latter [80].